First reported case series of Candida krusei peritonitis secondary to a perforated viscus


  • Pearl Wong Upper Gastrointestinal Department, Liverpool Hospital, Sydney, Australia
  • Rafael Gaszynski Upper Gastrointestinal Department, Bankstown-Lidcombe Hospital, Sydney, Australia
  • Andrew Gray Upper Gastrointestinal Department, Bankstown-Lidcombe Hospital, Sydney, Australia
  • Mark Ghali Upper Gastrointestinal Department, Bankstown-Lidcombe Hospital, Sydney, Australia
  • Yasser Farooque Upper Gastrointestinal Department, Liverpool Hospital, Sydney, Australia
  • Neil Merrett Upper Gastrointestinal Department, Bankstown-Lidcombe Hospital, Sydney, Australia



Candida peritonitis, Candida krusei, Anti fungal, Organ failure


Candida peritonitis is associated with high mortality and multiple organ failure. With an evolving epidemiology of candidaemia indicating an increasing prevalence of rare Candida species worldwide, consideration of multidrug-resistant fungal pathogens as a cause of abdominal sepsis is paramount. We report three cases of Candida krusei as a cause of secondary and tertiary peritonitis. These cases highlight that the early use of an echinocandin class antifungal in patients not responding to standard regimens warrants consideration.


Pramod J, Vijayakumar C, Srinivasan K, Maroju N, Raj Kumar N, Balasubramaniyan G. Clinical significance of candida in an intraoperative peritoneal specimen with perforation peritonitis: an institutional perspective. Cureus. 2018;10(3):e2275.

Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clinical Infectious Diseases. 2004;39 (Supplement-4):S185-92.

Pfaller M, Diekema D, Gibbs D, Newell V, Nagy E, Dobiasova S, et al. Candida krusei, a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Journal of Clinical Microbiology. 2007;46(2):515-21.

Pfaller M, Diekema D, Messer S, Boyken L, Hollis R, Jones R. In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from Blood. J Clin Microbiol. 2003;41(1):78-83.

Pfaller M, Diekema D. Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004; 42(10):4419-31.

Shan Y, Hsu H, Hsieh Y, Sy E, Lee J, Lin P. Significance of intraoperative peritoneal culture of fungus in perforated peptic ulcer. British J Surg. 2003;90(10):1215-9.

Pappas P, Kauffman C, Andes D, Clancy C, Marr K, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2015;62(4): e1-50.

Azim A, Ahmed A, Baronia A, Marak R, Muzzafar N. Intra-Abdominal Candidiasis. European Med J Nephrol. 2017;5(1):83-92.

Vergidis P, Clancy C, Shields R, Park S, Wildfeuer B, Simmons R, et al. Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. PLOS ONE. 2016;11(4): e0153247.

Montravers P, Mira J, Gangneux J, Leroy O, Lortholary O. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infection. 2011;17(7):1061-7.

Schuster M, Meibohm A, Lloyd L, Strom B. Risk factors and outcomes of Candida krusei bloodstream infection: A matched, case-control study. J Infection. 2013;66(3):278-84.

Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, Aznar-Martín J, et al. Risk Factors for Fluconazole-Resistant Candidemia. Antimicrobial Agents Chemotherap. 2010;54(8):3149-54.

Cornely O, Bassetti M, Calandra T, Garbino J, Kullberg B, Lortholary O, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infection. 2012;18(Supplement 7):19-37.

Orozco A, Higginbotham L, Hitchcock C, Parkinson T, Falconer D, Ibrahim A, Ghannoum M, Filler S. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother. 1998;42(10): 2645-49.

Oxman D, Chow J, Frendl G, Hadley S, Hershkovitz S, Ireland P, et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?. J Antimicrobial Chemotherap. 2010;65(7):1460-5.

Andes D, Safdar N, Baddley J, Playford G, Reboli A, Rex J, et al. Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials. Clin Infect Dis. 2012;54(8):1110-22.

Cascio A, Bartolotta M, Venneri A, Musolino C, Iaria C, Delfino D, et al. A case of Candida krusei peritonitis secondary to duodenal perforation due to Candida duodenitis. Mycopathologia. 2010;171(1): 51-5.






Case Reports